Hiv vaccine immunogens
OwnerHarry Gristick, Pamela J. Bjorkman +2inventors
InventorsHarry Gristick, Pamela J. Bjorkman, Harald Hartweger, Michel C. Nussenzweig
Life of this patent
Estimating the term…
Abstract
Provided herein are HIV immunogens and uses thereof for generating an immune response in a subject. This disclosure further provides a method for treating or preventing a human immunodeficiency type I (HIV-I) infection in a subject using the disclosed HIV immunogens and/or antibodies generated by any of the methods disclosed herein.
Claims35
An isolated polypeptide comprising an amino acid sequence that is at least 90% identical to the sequence of SEQ ID NO:
- 119, wherein the isolated polypeptide comprises at least an amino acid mutation in a position corresponding to D279, V430, D460, T461, T462, D463, or N464 of SEQ ID NO:
- 119.
-4. (canceled)
-8. (canceled)
-11. (canceled)
-22. (canceled)
-30. (canceled)
-40. (canceled)
A vaccine composition, comprising a carrier associated with a plurality of human immunodeficiency virus (HIV) immunogens, wherein the carrier is a monovalent or a multivalent carrier;
- and wherein the plurality of HIV immunogens comprise an isolated polypeptide comprising an amino acid sequence that is at least 90% identical to the sequence of SEQ ID NO:
- 129 or SEQ ID NO:
- 130.
-47. (canceled)
(canceled)
-64. (canceled)
A method for treating or preventing an HIV infection, or treating or preventing a disease or disorder caused by an HIV infection in a subject in need thereof, comprising:
- administering to the subject one or more vaccine compositions, thereby treating or preventing the HIV infection or the disease or disorder caused by the HIV infection in the subject, wherein the method comprises administering to the subject
- (a) a first vaccine composition comprising a carrier associated with a plurality of human immunodeficiency virus (HIV) immunogens, wherein the plurality of HIV immunogens comprise an isolated polypeptide comprising an amino acid sequence that is at least 90% identical to the sequence of SEQ ID NO:
- 129;
- (b) a second vaccine composition comprising a carrier associated with a plurality of human immunodeficiency virus (HIV) immunogens, wherein the plurality of HIV immunogens comprise an isolated polypeptide comprising an amino acid sequence that is at least 90% identical to the sequence SEQ ID NO:
- 130;
- (c) a third vaccine composition comprising a carrier associated with a plurality of human immunodeficiency virus (HIV) immunogens, wherein the plurality of HIV immunogens comprise an isolated polypeptide comprising an amino acid sequence that is at least 90% identical to the sequence SEQ ID NO:
- 131;
- and/or
- (d) a fourth and fifth vaccine composition each comprising a carrier associated with a plurality of human immunodeficiency virus (HIV) immunogens, comprising three, four, five, six, seven, or eight HIV immunogens, wherein each of the three, four, five, six, seven, or eight of HIV immunogens is derived from an HIV variant different from the other.
-67. (canceled)
-71. (canceled)
(canceled)
(canceled)
-83. (canceled)
-98. (canceled)
Dependencies are inferred from the claim text.